

Contents

Preface XIII

1	The Aims and Structure of Regulations	1
1.1	Introduction	1
1.2	Purpose and Principles of Regulation	1
1.3	The Legal Framework for Regulation	3
1.3.1	National Legislative Process	3
1.3.2	EU Legislative Process	4
1.3.3	Working with Legal Texts	5
1.3.4	Guidance Documents	6
1.3.5	Pharmacopoeia	7
1.4	Basic Legislation	7
1.4.1	EU Legislation	7
1.4.2	US Legislation	11
1.5	Scope of the Legislation	16
1.6	Chapter Review	19
1.7	Further Reading	19
2	Regulatory Strategy	21
2.1	Chapter Introduction	21
2.2	Basic Regulatory Strategy	21
2.2.1	Product Development	21
2.2.2	Product Manufacture	21
2.2.3	Market Vigilance	22
2.3	Quality Assurance Systems	22
2.3.1	Personnel	23
2.3.2	Documentation	24
2.3.3	Facilities and Equipment	25

2.3.4	Corrective and Preventive Action	25
2.4	Validation	26
2.5	Regulatory Bodies	27
2.5.1	European Commission	27
2.5.2	The EMEA	29
2.5.3	National Competent Authorities	30
2.5.4	Notified Bodies	32
2.5.5	The FDA	32
2.5.6	US Department of Agriculture	35
2.5.7	Pharmacopoeia Authorities	36
2.6	International Harmonisation Bodies	36
2.7	International Conference on Harmonisation	36
2.7.1	VICH	39
2.7.2	The Global Harmonisation Task Force	39
2.8	Pharmaceutical Inspection Cooperation Scheme	40
2.9	The World Health Organization (WHO)	42
2.10	Chapter Review	42
2.11	Further Reading	42
3	Drug Discovery and Development	43
3.1	Chapter Introduction	43
3.2	Drug Categorisation	43
3.2.1	Prescription Status	43
3.2.2	Physical Properties	44
3.2.3	Mode of Action	44
3.2.4	Therapeutic Use	45
3.3	Drug Discovery	45
3.4	Drug Development	50
3.5	Drug Delivery	52
3.5.1	Location	52
3.5.2	Drug Characteristics	52
3.5.3	Speed and Duration of Therapeutic Effect	53
3.5.4	Stability	55
3.6	Chapter Review	55
3.7	Suggested Reading	55
4	Non-Clinical Studies	57
4.1	Chapter Introduction	57
4.2	Non-Clinical Study Objectives and Timing	57
4.3	Pharmacological Studies	58
4.3.1	Pharmacodynamic Studies	59
4.3.2	Pharmacokinetic/Toxicokinetic Studies	62
4.4	Bioavailability and Bioequivalence	64
4.5	Toxicology Studies	65

4.5.1	Toxicity Studies	65
4.5.2	Genotoxicity Studies	66
4.5.3	Carcinogenicity Studies	67
4.5.4	Reproductive Toxicology Studies	67
4.6	Chemistry, Manufacturing and Control Development (CMC)	67
4.7	Quality of Biotech Products	68
4.7.1	Stability Studies	68
4.8	Good Laboratory Practice (GLP)	69
4.9	Chapter Review	69
4.10	Further Reading	71
5	Clinical Trials	73
5.1	Chapter Introduction	73
5.2	Clinical Trials	73
5.2.1	Phase I Trials	74
5.2.2	Phase II Trials	74
5.2.3	Phase III Trials	75
5.3	Clinical Trial Design	76
5.4	Good Clinical Practice	78
5.5	Clinical Trials in the EU	78
5.5.1	The Sponsor	80
5.5.2	The Investigator's Brochure	80
5.5.3	The Investigator	81
5.5.4	The Trial Protocol	81
5.5.5	The Investigational Medicinal Product Dossier	82
5.5.6	Informed Consent	82
5.5.7	Manufacture of Investigational Medicinal Product	82
5.5.8	Competent Authority Clinical Trial Application	84
5.5.9	Independent Ethics Committee CTA	85
5.5.10	Amendments to Clinical Trials	87
5.5.11	Case Report Forms	87
5.5.12	Adverse Event Reporting	87
5.5.13	Annual Safety Report	88
5.5.14	Monitoring of Trials	88
5.5.15	End of Trial	88
5.5.16	Trial Master File	88
5.6	Clinical Trials in The US	89
5.6.1	Investigational New Drug Application (IND)	89
5.6.2	Institutional Review Board	91
5.6.3	Communication with the FDA	94
5.6.4	Labelling of Investigational Drugs	95
5.7	Chapter Review	95
5.8	Further Reading	95

6	Marketing Authorisation	97
6.1	Chapter Introduction	97
6.2	The Application Dossier	97
6.3	CTD	98
6.3.1	Module Structure	101
6.3.2	Module 3: Quality	101
6.3.3	Drug Master Files	104
6.3.4	Module 4: Non-Clinical Study Reports	105
6.3.5	Module 5: Clinical Study Reports	105
6.3.6	Module 2: Summaries	107
6.3.7	Module I: Region-Specific	110
6.3.8	Module 1: EU	110
6.3.9	Module 1: US	113
6.4	Submission and Review Process in the EU	114
6.4.1	Community Authorisation	114
6.4.2	Scientific Evaluation Process	119
6.4.3	Decision-Making Process	120
6.4.4	National Authorisations	121
6.4.5	Decentralised Procedure	121
6.4.6	Mutual Recognition Procedure	123
6.4.7	Plasma Master Files and Vaccine Antigen Master Files	124
6.5	Submission and Review Process in the US	124
6.6	Chapter Review	127
6.7	Further Reading	127
7	Authorisation of Veterinary Medicines	129
7.1	Chapter Introduction	129
7.2	Overview of Development Process for Veterinary Medicines	129
7.2.1	Pre-Clinical Studies	130
7.2.2	Clinical Trials	131
7.2.3	Good Clinical Practices	131
7.3	Authorisation of Clinical Trials in the EU	134
7.4	Authorisation of Clinical Trials in the US	135
7.5	Maximum Residue Limits	136
7.6	Authorisation of Veterinary Medicines in the EU	138
7.6.1	Applications to Establish MRLs	138
7.6.2	Review of Applications and Establishment of MRLs	138
7.6.3	Marketing Authorisations	142
7.6.4	Presentation of the Dossier	143
7.7	Approval of Veterinary Medicines in the US	144
7.7.1	New Animal Drug Application	144
7.7.2	Approval of Veterinary Biological Products	147
7.8	Chapter Review	148
7.9	Further Reading	148

8	Variations to the Drug Authorisation Process	149
8.1	Chapter Introduction	149
8.2	Provisions in Support of Special Drug Applications	149
8.2.1	Orphan Drugs	149
8.3	Accelerated Access to New Drug Therapies	151
8.3.1	EMA Accelerated Review	151
8.3.2	Compassionate Use	151
8.3.3	Fast-Track Products	152
8.3.4	Treatment INDs	152
8.3.5	Paediatric Applications	152
8.4	Approval of New Drugs when Human Efficacy Studies are not Ethical or Feasible	153
8.5	Animal Drugs for Minor Use and Minor Species	153
8.5.1	Conditional Approval	153
8.5.2	Indexing	154
8.5.3	Designation	154
8.6	Use of Non-Authorised Drugs for Animal Treatment in the EU	154
8.7	Changes to an Authorised Drug	154
8.8	EU System for Processing Changes	154
8.8.1	Extension Applications	155
8.8.2	Major Variation (Type II)	155
8.8.3	Minor Variation (Type IA or IB)	156
8.9	Processing Changes in the US	156
8.9.1	Manufacturing Change Supplements	156
8.9.2	Major Changes	157
8.9.3	Moderate Changes	157
8.9.4	Minor Changes	157
8.10	Authorisation of Generic Drugs	158
8.10.1	EU Regulations	158
8.10.2	US Regulations	159
8.11	Reference Drug Exclusivity	159
8.12	Other Authorisation Procedures	161
8.12.1	Well-Established Medical Use Products	161
8.12.2	Combination Products	161
8.12.3	Homeopathic Medicines	161
8.12.4	Traditional Herbal Medicines	162
8.12.5	US Regulation of OTC Drugs	162
8.13	Chapter Review	164
8.14	Further Reading	164
9	Medical Devices	167
9.1	Chapter Introduction	167
9.2	Regulatory Strategy for Medical Devices in the EU	167
9.2.1	Use of Standards to Establish Conformity	168
9.2.2	Classification of Devices	170

9.3	Regulatory Strategy for Medical Devices in the US	173
9.3.1	Classification of Devices	173
9.3.1.1	Class I Devices	176
9.3.1.2	Class II Devices	177
9.3.1.3	Class III Devices	178
9.3.2	Classification of New Devices	178
9.4	Development of Devices	178
9.4.1	Design Controls	180
9.4.2	Design and Development Planning	180
9.4.3	Design Input	182
9.4.4	Design Output	182
9.4.5	Design Verification and Design Validation	183
9.4.6	Design Review	183
9.4.7	Risk Analysis	184
9.4.8	Design Changes	185
9.5	Chapter Review	185
9.6	Further Reading	185
10	Authorisation of Medical Devices	187
10.1	Chapter Introduction	187
10.2	Evaluation of Medical Devices in Europe	187
10.2.1	Clinical Investigations	188
10.2.2	Performance Evaluations	190
10.3	Evaluation of Medical Devices in the US	191
10.3.1	IDE-Exempted Investigations	191
10.3.2	Abbreviated Requirement Investigations	192
10.3.3	IDE Investigations	192
10.3.4	Labelling of Devices for Investigational Use	193
10.4	Placing of Devices on the Market in the EU	194
10.4.1	Conformity Assessment Procedures	195
10.4.2	Full Quality Assurance	197
10.4.3	EC Type-Examination	197
10.4.4	Production Quality Assurance	199
10.4.5	EC Verification	199
10.4.6	Product QA	199
10.4.7	EC (Self) Declaration of Conformity	199
10.4.8	Technical Documentation	199
10.4.9	Labelling Requirements	200
10.4.10	Competent Authority Notifications and the European Databank	201
10.5	Placing of Devices on the Market in the US	202
10.5.1	510(k) Pre-market Notification	202
10.5.1.1	Traditional 510(k)	202
10.5.1.2	Abbreviated 510(k)	203
10.5.1.3	Special 510(k)	203
10.5.1.4	De Novo 510(k)	203

10.5.2	Notification and Review Procedures	203
10.5.3	Pre-market Approval (PMA)	203
10.5.4	Changes to a PMA-Approved Device	205
10.5.5	Humanitarian Use Devices	206
10.5.6	Labelling of Devices	206
10.6	Chapter Review	206
10.7	Further Reading	208
11	Good Manufacturing Practice (GMP)	209
11.1	Chapter Introduction	209
11.2	Drug GMP Regulations and Guidance	209
11.3	Essential GMP Requirements	212
11.3.1	Quality Assurance System	212
11.3.2	Personnel	212
11.3.3	Premises and Equipment	213
11.3.4	Documentation	221
11.3.5	Production	222
11.3.6	Quality Control	222
11.3.7	Work Contracted Out	222
11.3.8	Complaints, Product Recall and Emergency Un-Blinding	223
11.3.9	Self-Inspection	223
11.4	Validation	223
11.4.1	Facilities and Equipment Validation	225
11.4.2	Process Validation	225
11.4.3	Computer Systems Validation	226
11.4.4	Methods Validation	227
11.4.5	Cleaning Validation	229
11.4.6	Validation of Sterilisation Procedures	230
11.4.7	Water Purification System Validation	230
11.5	GMP Requirements for Devices	231
11.6	Chapter Review	234
11.7	Further Reading	235
12	Oversight and Vigilance	237
12.1	Chapter Introduction	237
12.2	Registration of Manufacturers and Other Entities	237
12.3	Manufacturing Authorisation of Medicinal Products in the EU	237
12.3.1	Wholesale Distribution of Medicinal Products	238
12.3.2	Registration of Persons Responsible for Placing Medical Devices on the EU Market	240
12.4	Registration of Producers of Drugs and Devices in the US	241
12.4.1	Additional Licensing Requirements	242
12.5	Inspections	242
12.5.1	Inspection Techniques	245
12.5.2	Audit Findings and Consequences	248

12.6	Market Vigilance and Oversight of Drugs	253
12.6.1	Pharmacovigilance in the EU	254
12.6.2	Qualified Person	254
12.6.3	Reporting Requirements	254
12.6.4	Expedited Reports	255
12.6.5	Periodic Safety Update Reports	256
12.6.6	Safety Study Reports	256
12.6.7	Response to Issues	256
12.6.8	Renewal of Marketing Authorisations	258
12.6.9	Reporting Requirements in the US	258
12.6.10	Expedited Reports	258
12.6.11	Periodic Reports	262
12.7	Advertising and Promotion	262
12.8	Market Vigilance and Oversight of Devices	262
12.8.1	Market Vigilance in the EU	263
12.8.2	Medical Device Vigilance in the US	271
12.8.3	Medical Device Reporting	272
12.8.4	Reports of Corrections and Removals	273
12.8.5	Post-Market Surveillance	273
12.9	Chapter Review	274
12.10	Further Reading	274

Index	277
--------------	-----